Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX
15th International Podocyte Conference and 2025 ISGD Meeting
June 10 - 13, 2025
Germany
Travere and National Kidney Foundation Collaboration
Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)
American Nephrology Nurses Association (ANNA) National Symposium 2025
May 1 - 4, 2025
OR
Patient-Reported Outcomes in Rare Kidney Disease Clinical Trials: Sparsentan Versus Irbesartan
National Kidney Foundation (NKF) Spring Clinical Meetings 2025
April 10 - 13, 2025
Boston
Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Patients with Focal Segmental Glomerulosclerosis
Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan
Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)
Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy